Last reviewed · How we verify
without triamcinolone
This drug is a corticosteroid that suppresses inflammation and immune responses.
This drug is a corticosteroid that suppresses inflammation and immune responses. Used for Asthma, Allergic rhinitis, Atopic dermatitis.
At a glance
| Generic name | without triamcinolone |
|---|---|
| Also known as | Placebo |
| Sponsor | Peking University Third Hospital |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Dermatology, Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone is a synthetic glucocorticoid that has potent anti-inflammatory and immunosuppressive properties. It works by binding to glucocorticoid receptors in cells, which then translocate to the nucleus and regulate the expression of genes involved in inflammation and immune responses.
Approved indications
- Asthma
- Allergic rhinitis
- Atopic dermatitis
- Multiple sclerosis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Cushing's syndrome
- Adrenal insufficiency
- Glaucoma
- Osteoporosis
- Hypokalemia
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Efficacy and Safety of Myopic Macular Hole Closure Surgery Without Endotamponade Agent (NA)
- The Effect of Local Corticosteroid Injection in Carpal Tunnel Syndrome Patients With Type 2 Diabetes
- A Superiority Trial of Radiofrequency Ablation for Low Back Pain (NA)
- The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis (PHASE3)
- Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer (PHASE2)
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
- The Effect of Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |